-
Jeffrey Schlom, PhD
-Chief of Laboratory of Tumor Immunology and Biology at NCI. Principal Investigator on awarded Syntrix-NCI CRADA to fund SX-682 through Phase II.
0 -
Elizabeth Mittendorf, MD, PhD
-Surgical oncologist focused on breast cancer immunotherapy. Principal Investigator and key design lead of SX-682 Phase I/II breast cancer trial.
-
Rami Komrokji, MD
-Professor and head of the Leukemia and MDS Section at the Moffitt Cancer Center. Principal Investigator of SX-682 MDS Phase I/II trial.
-
-
Dimitry Gabrilovitch, MD, PhD
-Leads Wistar’s Translational Tumor Immunology Program. MDSC pioneer and co-investigator in SX-682 melanoma trial.
-
-
Ronald DePinho, MD
-Partner laboratory on SX-682 prostate cancer Nature paper. Former President of MD Anderson Cancer Center.
-
Martin “Mac” Cheever, MD
-Principal Investigator of the National Cancer Institute-funded Cancer Immunotherapy Trials Network.